Boston Scientific Corporation (BSX) Receives News Impact Score of 0.24
News coverage about Boston Scientific Corporation (NYSE:BSX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific Corporation earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 44.9346989427071 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Boston Scientific Corporation (BSX) EVP Sells $10,108,629.44 in Stock (americanbankingnews.com)
- Now, a brain pacemaker that reduces tremors and helps Parkinson’s sufferers lead a more normal life (finance.yahoo.com)
- JANG v. BOSTON SCIENTIFIC CORPORATION (leagle.com)
- Boston Scientific ups ante in AF space with $300M cash and milestone Apama acquisition (medicaldevicedaily.com)
- Boston Scientific Corporation (BSX) – Ownership Status Turns Critical – Wallstreet Investorplace (wallstreetinvestorplace.com)
Several research analysts have recently issued reports on BSX shares. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. J P Morgan Chase & Co restated an “overweight” rating and issued a $31.00 price target (up from $27.00) on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Jefferies Group LLC restated a “hold” rating on shares of Boston Scientific Corporation in a research report on Thursday, September 7th. Royal Bank Of Canada restated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Finally, BidaskClub lowered Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation currently has an average rating of “Buy” and a consensus target price of $30.06.
Shares of Boston Scientific Corporation (NYSE BSX) traded up 0.24% during mid-day trading on Friday, reaching $29.50. The company had a trading volume of 4,980,172 shares. The firm has a market capitalization of $40.48 billion, a price-to-earnings ratio of 52.77 and a beta of 1.09. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.54. The stock has a 50 day moving average of $28.30 and a 200-day moving average of $26.99.
Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.27 EPS. Equities analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.
In other news, SVP John Bradley Sorenson sold 2,100 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $27.15, for a total transaction of $57,015.00. Following the transaction, the senior vice president now owns 18,880 shares of the company’s stock, valued at approximately $512,592. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Wendy Carruthers sold 12,433 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total transaction of $332,582.75. The disclosure for this sale can be found here. Insiders have sold a total of 623,455 shares of company stock worth $17,676,597 in the last three months. Insiders own 0.74% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-receives-news-impact-score-of-0-24/1613949.html.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.